180587-74-0

Basic information

• Product Name: (R)-1-(6-chloro-9H-purin-9-yl)propan-2-ol
• Synonyms: (R)-1-(6-chloro-9H-purin-9-yl)propan-2-ol;9H-Purine-9-ethanol, 6-chloro-a-Methyl-, (aR)-
• CAS NO: 180587-74-0
• Molecular Formula: C₈H₉ClN₄O
• Molecular Weight: 212.63626
• Mol File: 180587-74-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-1-(6-chloro-9H-purin-9-yl)propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(6-chloro-9H-purin-9-yl)propan-2-ol(180587-74-0)
• EPA Substance Registry System: (R)-1-(6-chloro-9H-purin-9-yl)propan-2-ol(180587-74-0)

Safety Data

• Hazardous Substances Data: 180587-74-0(Hazardous Substances Data)

Usage

General Description

(R)-1-(6-chloro-9H-purin-9-yl)propan-2-ol is a chemical compound with the molecular formula C10H12ClN5O. It is a derivative of purine and has a chiral center, making it exist as a pair of enantiomers. (R)-1-(6-chloro-9H-purin-9-yl)propan-2-ol is commonly used as a research tool in the study of purinergic signaling and as a building block in the synthesis of nucleoside analogs. It has also been investigated for its potential pharmacological properties, including its effects on adenosine receptors and its potential as an anti-cancer agent. The compound is a white to off-white solid and is typically handled and stored under controlled conditions due to its potential reactivity and toxicity.

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 17435-30-2 (R)-1-(5-Amino-6-chloro-pyrimidin-4-ylamino)-propan-2-ol 
• 87-42-3 6-chloropurine 
• 100682-42-6 1-(6-chloro-9H-purin-9-yl)-2-propanone 

Downstream Products

• 180587-75-1 (R)-diethyl (((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate 
• 147127-20-6 tenofovir 
• 14047-28-0 (R)-9-(2-hydroxypropyl)adenine 

Relevant articles and documents

Preparation method for tenofovir

The invention relates to the field of chemical synthesis, and in particular relates to a preparation method for tenofovir. The compound provided by the invention has a structure shown by a formula XIIin the description. The method for preparing the tenofovir based on a compound provided by the invention has the advantages that raw materials are cheap and easy to obtain, the process route is short, the conditions are mild and reliable, and the method is easily used for industrialized production.

The synthesis of tenofovir and its analogues via asymmetric transfer hydrogenation

A series of tenofovir analogues with potential antiviral and immunobiologically active compounds were synthesized through an asymmetric transfer hydrogenation reaction from achiral purine derivatives. Up to 97% ee and good to excellent yields were achieved under mild conditions through short reaction steps. The present report suggests an efficient process to acquire tenofovir and its analogues.